Cost-Per-Responder Analysis of Bimekizumab (IL-17A/F inhibitor) against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, based on Matching-Adjusted Indirect Comparisons (MAIC)
Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)
Recommendations for effective patient involvement in the assessment of medical devices
Costs of the Management of Hemophilia a with Inhibitors in Spain
Budget IMPACT Analysis of LESS Invasive Surfactant Administration (LISA) Technique As EARLY Rescue Strategy for Preterm Infants with Respiratory Distress Syndrome in Spain
Comparative Narrative Review of Oncology Value Assessment Frameworks: Enfortumab Vedotin (EV) for Treatment of Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Budget impact analysis of a transanal irrigation for the treatment of low anterior resection syndrome in Spain
The clinical and economic value of a sustained response in the treatment of moderate-to-severe psoriasis in Spain: The Psovalue project
Budget Impact Analysis of a Solution for Sealant in Spain
An ideal and sustainable framework agreement for the public procurement of vaccines in Spain
